Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
603259 WuXi AppTec
71.690
-0.860-1.19%
YOY
Do not show
Hide blank lines
(Q6)2022/06/30(Q3)2022/03/31(FY)2021/12/31(Q9)2021/09/30
Assets
Current assets
Money funds
-27.71% 7.09B -34.19% 7.03B -19.52% 8.24B -37.91% 8.37B
Transactional financial assets
-98.14% 40.63M -86.91% 276.26M -88.58% 527.29M -27.51% 2.19B
Notes receivable and accounts receivable
55.56% 6.49B 65.59% 6.41B 27.28% 4.67B 24.79% 4.51B
-Notes receivable
6451.16% 117.27M 6150% 25M 1820% 48M 74.75% 6.23M
-Accounts receivable
52.82% 6.37B 64.96% 6.39B 26.05% 4.62B 24.74% 4.5B
Other receivables (including interest and dividends)
-46.61% 48.55M 521.97% 315.13M 901.24% 339.58M 43.36% 75.88M
-Dividend receivable
-- -- -- -- -- 0 -- --
-Accrued interest receivable
-- -- -- -- -98.3% 38.28K -97.87% 49.71K
-Other receivable
-46.61% 48.55M -- -- 972.17% 339.54M -- --
Contractual assets
26.86% 862.75M 39.54% 843.76M 42.71% 773.43M 49.36% 761.69M
Advance payment
6.93% 369.75M 34.03% 346.73M 72.37% 302.91M 64.66% 281.29M
Inventories
100.18% 7.28B 107.94% 6.41B 119.86% 5.91B 91.37% 4.52B
Non-current assets due within one year
-- 545.36M -- -- -- -- -- --
Other current assets
73.33% 932.3M 119.04% 1.11B 86.63% 1B 23.66% 646.95M
Total current assets
8.61% 23.68B 6.93% 23.04B -4.66% 21.99B -10.2% 21.54B
Non Current assets
Other non-current financial assets
-1.3% 9.34B 3.84% 8.56B 29.73% 8.71B 53.21% 8.91B
Long-term equity investment
15.92% 1.14B -22% 581.77M -11.31% 678.3M -2.92% 802.48M
Fixed assets
58.09% 10.37B -- -- 49.8% 8.55B -- --
Fixed assets liquidation
-- 0 -- -- -- 0 -- --
Constru in process
86.46% 8.13B -- -- 87.02% 5.77B -- --
Construction materials
-- 0 -- -- -- 0 -- --
Productive biological assets
51.57% 956.85M 81.19% 824.03M 75.12% 733.51M 73.64% 651.57M
Intangible assets
2.52% 1.63B 23.45% 1.63B 60.35% 1.6B 58.12% 1.6B
Goodwill
-1.71% 1.92B -3.02% 1.91B 38.35% 1.93B 33.24% 1.94B
Long deferred expense
18.29% 1.58B 12.07% 1.52B 13.4% 1.54B 5% 1.33B
Deferred tax assets
50.58% 474.31M 20.56% 418.72M 29.56% 389.85M -1.32% 293.11M
Usufruct assets
-3.3% 1.03B 3.33% 1.12B -3.43% 1.07B -4.71% 1.1B
Other non current assets
-21.4% 1.67B 3.89% 2.19B 57.03% 2.17B 280.83% 2.14B
Total non current assets
25.87% 38.24B 27.63% 34.54B 42.66% 33.14B 54.11% 31.63B
Total assets
18.66% 61.91B 18.46% 57.58B 19.09% 55.13B 19.45% 53.17B
Liabilities
Current liabilities
Short term loan
26.41% 2.87B 75.72% 2.69B 83.86% 2.26B 51.74% 2.3B
Notes payable and accounts payable
156.94% 3.43B 114.87% 2.44B 105.12% 1.93B 80.48% 1.51B
-Accounts payable
160.03% 3.43B 114.99% 2.44B 107.7% 1.93B 83.07% 1.51B
Contract liabilities
60.7% 3.23B 101.62% 3.3B 88.89% 2.99B 98.91% 2.55B
Salaries payable
13.34% 1.28B 30.94% 982.09M 38.69% 1.58B 59.4% 1.34B
Taxs payable
83.09% 732.82M 52.89% 881.18M 41.56% 536.01M 34.31% 468.85M
Other payable (including interest and dividends)
30.24% 3.77B 20.6% 2.92B 34% 3.29B 22.49% 2.79B
-Interest payable
78.47% 1.42M 222.26% 1.85M 57.75% 1.34M -58.29% 1.21M
-Dividend payable
-- 0 -- -- -- 0 -- --
-Other payable
30.23% 3.77B -- -- 33.99% 3.29B -- --
Non current liabilities due within one year
157.81% 428.19M 118.8% 386.03M 123.42% 396.42M -7.7% 172.51M
Total current liabilities
58.65% 16.2B 64.36% 13.6B 63.94% 12.98B 51.5% 11.14B
Current liabilities
Bonds payable
-31.69% 646.83M -53.39% 606.28M -66.62% 607.14M -59.83% 755.62M
Deferred tax liabilities
11.85% 399.62M -1.83% 299.94M 14.54% 324.13M 22.81% 293.7M
Long term deferred income
28.61% 873.91M 14.12% 763.79M 12.99% 770.6M -0.09% 681.09M
Lease liabilities
-6.8% 987.61M 2.65% 1.09B -4.51% 1.02B -1.97% 1.09B
Other non current liabilities
-78.91% 408.67M -60.9% 575.36M -63.11% 664.49M 35.52% 1.57B
Total non current liabilities
-33.41% 3.32B -30.61% 3.34B -40.11% 3.39B -13.43% 4.4B
Exceptional items of total current liabilities
-- 0 -- 0 -- 0 -- 0
Total liabilities
28.47% 19.52B 29.42% 16.94B 20.61% 16.37B 24.98% 15.53B
Shareholders equity
Paid-in capital
0.26% 2.96B 20.62% 2.96B 21.06% 2.96B 20.92% 2.95B
Capital reserve funds
6.62% 26.29B 7.85% 25.96B 13.47% 25.73B 12.27% 25.32B
Surplus reserve funds
70.94% 408.36M 70.94% 408.36M 70.94% 408.36M 63.39% 238.9M
Retained profit
54.48% 15.25B 43.61% 13.77B 49.93% 12.13B 41.8% 10.76B
Less:Treasury stock
138.93% 2.26B 105.75% 2.45B 106.67% 2.46B 68.07% 1.74B
Other composite income
-1380.12% -564.71M -305.98% -279.95M -214.55% -271.42M -178.89% -156.12M
Shareholders equity without minority interests
14.56% 42.08B 14.37% 40.36B 18.46% 38.49B 17.2% 37.38B
Minority interests
24.22% 312.91M 22.31% 283.29M 18.33% 265.95M 36.82% 257.76M
Total shareholder equity
14.63% 42.39B 14.42% 40.65B 18.46% 38.76B 17.31% 37.64B
Total liabilityies and equity
18.66% 61.91B 18.46% 57.58B 19.09% 55.13B 19.45% 53.17B
Currency Unit
CNYCNYCNYCNY
Accounting Standards
CAS (2007)CAS (2007)CAS (2007)CAS (2007)
Audit Opinions
----Unqualified opinion--
Auditor
----Deloitte Huayong Accounting firm (Special General Partnership)--

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
The company, formerly known as Wuxi Yao Ming Kang de New Drug Development Co., Ltd., was invested and established in Wuxi, Jiangsu Province in December 2000. The company is an international leading open capability and technology platform, providing omni-directional and integrated new drug R & D and production services for the global biomedical industry. Through cost-effective and efficient R & D services, the company helps customers improve R & D efficiency, covering chemical drug R & D and production, cell and gene therapy R & D and production, medical device testing and other fields. The company's honors include Baihua Association "Enterprise of the year Award", Sina Pharmaceutical as "the most influential Enterprise in China Pharmaceutical Industry", and 51job as "China's 100th Model employer" for four consecutive years.
CEO: --
Market: --
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...